U.S. markets closed
  • S&P Futures

    3,885.50
    -13.25 (-0.34%)
     
  • Dow Futures

    31,406.00
    -103.00 (-0.33%)
     
  • Nasdaq Futures

    13,248.25
    -31.50 (-0.24%)
     
  • Russell 2000 Futures

    2,260.30
    -14.50 (-0.64%)
     
  • Crude Oil

    59.69
    -0.95 (-1.57%)
     
  • Gold

    1,707.50
    -15.50 (-0.90%)
     
  • Silver

    26.10
    -0.57 (-2.15%)
     
  • EUR/USD

    1.2025
    -0.0035 (-0.29%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3886
    -0.0035 (-0.25%)
     
  • USD/JPY

    106.7920
    +0.0620 (+0.06%)
     
  • BTC-USD

    48,970.83
    +2,168.22 (+4.63%)
     
  • CMC Crypto 200

    980.54
    +52.31 (+5.64%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,554.75
    -108.75 (-0.37%)
     

LGND or ALKS: Which Is the Better Value Stock Right Now?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Ligand Pharmaceuticals (LGND) and Alkermes (ALKS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Ligand Pharmaceuticals has a Zacks Rank of #2 (Buy), while Alkermes has a Zacks Rank of #3 (Hold) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that LGND has an improving earnings outlook. But this is just one factor that value investors are interested in.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

LGND currently has a forward P/E ratio of 23.88, while ALKS has a forward P/E of 195.64. We also note that LGND has a PEG ratio of 1.59. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ALKS currently has a PEG ratio of 73.27.

Another notable valuation metric for LGND is its P/B ratio of 2.29. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, ALKS has a P/B of 2.43.

These are just a few of the metrics contributing to LGND's Value grade of B and ALKS's Value grade of C.

LGND has seen stronger estimate revision activity and sports more attractive valuation metrics than ALKS, so it seems like value investors will conclude that LGND is the superior option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
Alkermes plc (ALKS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.